Skip to main content

Table 3 Associations between baseline plasma lnMMP-1, -2, -3, -9 and -10 and lnTIMP-1 and all-cause mortality (n=83)

From: Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

Model MMP-1 MMP-2 MMP-3 MMP-9 MMP-10 TIMP-1
HR 95% CI p va ue HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value
1 1.62 1.28; 2.06 <0.001 1.93 1.48; 2.51 <0.001 1.82 1.38; 2.41 <0.001 1.39 1.14; 1.69 0.001 1.33 1.06; 1.67 0.015 2.10 1.55; 2.85 <0.001
2 1.38 1.07; 1.78 0.012 1.60 1.19; 2.15 0.002 1.39 1.05; 1.85 0.021 1.18 0.95; 1.46 0.133 1.13 0.90; 1.41 0.313 1.39 0.97; 1.98 0.070
3 1.45 1.10; 1.92 0.008 1.50 1.07; 2.09 0.017 1.32 0.95; 1.83 0.100 1.17 0.93; 1.46 0.179 1.01 0.78; 1.30 0.943 1.15 0.75; 1.74 0.529
4 1.34 1.04; 1.73 0.026 1.57 1.17; 2.10 0.002 1.40 1.06; 1.86 0.019 1.12 0.90; 1.40 0.314 1.12 0.90; 1.41 0.316 1.29 0.89; 1.87 0.173
5 1.47 1.13; 1.92 0.004 1.58 1.17; 2.12 0.002 1.41 1.07; 1.87 0.015 1.18 0.95; 1.45 0.132 1.13 0.90; 1.41 0.307 1.33 0.93; 1.92 0.118
  1. HR hazard ratio for all-cause mortality per 1 SD increase in lnMMP-1, -2, -3, -9 or -10 or lnTIMP-1, MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
  2. Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
  3. Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
  4. Model 3 Model 2 + eGFR and Ln-UAE
  5. Model 4 Model 2 + inflammatory z-score
  6. Model 5 Model 2 + endothelial dysfunction z-score